+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin



Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin



Biophysical Chemistry 88(1-3): 61-67, 15 December



Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant hereditary type of amyloidosis involving amino acid substitutions in transthyretin (TTR). V30M-TTR is the most frequent variant, and L55P-TTR is the variant associated with the most aggressive form of FAP. The thermal stability of the wild-type, V30M-TTR, L55P-TTR and a non-amyloidogenic variant, T119M-TTR, was studied by high-sensitivity differential scanning calorimetry (DSC). The thermal unfolding of TTR is a spontaneous reversible process involving a highly co-operative transition between folded tetramers and unfolded monomers. All variants of transthyretin are very stable to the thermal unfolding that occurs at very high temperatures, most probably because of their oligomeric structure. The data presented in this work indicated that for the homotetrameric form of the wild-type TTR and its variants, the order of stability is as follows: wild-type TTR gtorsim T119M-TTR > L55P-TTR > V30M-TTR, which does not correlate with their known amyloidogenic potential.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010351076

Download citation: RISBibTeXText

DOI: 10.1016/s0301-4622(00)00199-x


Related references

Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophysical Chemistry 88(1-3): 61-67, 2000

Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. Amyloid 5(3): 175-187, 1998

Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11(1): 1-9, 2004

Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Bioscience Reports 35(1):, 2015

Amyloidogenic and non-amyloidogenic transthyretin Asn 90 variants. Clinical Genetics 42(1): 27-30, 1992

Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. Journal of Biological Chemistry 284(3): 1443-1453, 2009

The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proceedings of the National Academy of Sciences of the United States of America 97(12): 6445-6450, 2000

Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System. Frontiers in Neuroscience 11: 119, 2017

Transthyretin Asn90 variant: amyloidogenic or non-amyloidogenic role. Journal of the Neurological Sciences 284(1-2): 113-115, 2009

A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. Journal of Molecular Biology 302(3): 649-669, 2000

The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Letters 418(3): 297-300, 1997

Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses. Journal of Biological Chemistry 284(38): 25832-25841, 2009

The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. Febs Letters 418(3): 297-300, 1997

Inhibition of intracellular tetramerization induces the proteasomal degradation of amyloidogenic transthyretin variants. 2008

An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid 10(3): 190-197, 2003